At the news
? NEUTRALIMPACT 2/10 144 filed Nov 2, 2026 at 16:26 ET
Jason Aryeh, a director of Ligand Pharmaceuticals, filed a Form 144 notice of intent to sell 700 shares of Class B common stock, with an approximate market value of $221,595. The shares were acquired between May and July 2019 via secondary market purchases. The sale is small relative to the company's $6.3B market cap and the insider's likely total holdings, making it a routine diversification move.
- Jason Aryeh, a director, filed Form 144 to sell 700 shares of Class B common stock.
- Estimated proceeds of $221,595 based on filing date price.
- Shares were acquired between May 14, 2019 and July 30, 2019 via secondary market purchases.
- The sale represents a tiny fraction of the company's $6.3B market cap.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access